Filoviruses are the causative agents of highly lethal outbreaks in sub-Saharan Africa. Although an experimental vaccine and several therapeutics are being deployed in the Democratic Republic of Congo to combat the ongoing Ebola virus outbreak, these therapies are specific for only one filovirus species. There is currently significant interest in developing broadly reactive monoclonal antibodies (mAbs) with utility against the variety of ebolaviruses that may emerge. Thus far, the primary target of these mAbs has been the viral spike glycoprotein (GP). Here we present an overview of GP-targeted antibodies that exhibit broad reactivity and the structural characteristics that could confer this cross-reactivity. We also discuss how these structural features could be leveraged to design vaccine antigens that elicit cross-reactive antibodies.

丝状病毒是撒哈拉以南非洲高度致死性暴发的病原体。尽管在刚果民主共和国已部署了实验疫苗和几种疗法来对抗持续的埃博拉病毒爆发，但这些疗法仅针对一种丝状病毒。目前，人们对开发广泛反应的单克隆抗体（mAb）具有极大的兴趣，该抗体可抗可能出现的多种埃博拉病毒。迄今为止，这些mAb的主要靶标是病毒刺突糖蛋白（GP）。在这里，我们介绍了GP靶向抗体的概述，这些抗体表现出广泛的反应性和可以赋予这种交叉反应性的结构特征。我们还将讨论如何利用这些结构特征来设计引起交叉反应抗体的疫苗抗原。